The US Food and Drug Administration has approved a treatment for chronic hepatitis delta virus infection. This approval is for Hepcludex injection, which is intended for adults with the condition who do not have cirrhosis or have compensated cirrhosis. The treatment was approved for Gilead Sciences, the company that developed Hepcludex. This development is related to the treatment of chronic hepatitis delta virus infection in a specific patient population. The approved treatment is for use in adults without severe liver damage, providing a new option for managing the infection in this group.

AI summaries can be wrong sometimes—always verify important details using the source article.